Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties
platform to transform oncology drug discovery and development today announced that it has filed seven patent applications globally on a novel DNA-damaging agent with anticancer properties.
- platform to transform oncology drug discovery and development today announced that it has filed seven patent applications globally on a novel DNA-damaging agent with anticancer properties.
- Based on Lantern's previously filed PCT ("Patent Cooperation Treaty") patent application, Lantern has filed national stage patent applications to seek protection for LP-284 in major market countries throughout the world.
- The national stage patent applications allow, if granted, for patent protection of LP-284.The filed, multi-national patent applications are directed to both the composition and manufacture of LP-284.
- These seven patent applications are consistent with our focus on becoming a leader in the global development of precision oncology therapies," said Mr. Sharma of Lantern Pharma.